Thyroid over-expression of type 1 and type 2 deiodinase may account for the syndrome of low thyroxine and increasing triiodothyronine during propylthiouracil treatment

European Journal of Endocrinology

Volumn 149, Issue 5, 2003, Pages 443-447

  Weetman, A P ^a   Shepherdley, C A ^b   Mansell, P ^c   Ubhi, C S ^d   Visser, T J ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; LIOTHYRONINE; PROPRANOLOL; PROPYLTHIOURACIL; THYROID STIMULATING IMMUNOGLOBULIN; THYROXINE; THYROXINE DEIODINASE;

ADULT; ARTICLE; CASE REPORT; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; GOITER; GRAVES DISEASE; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; PRIORITY JOURNAL; RASH; THYROIDECTOMY; THYROTOXICOSIS;

ADULT; ANTITHYROID AGENTS; ENZYME ACTIVATION; FEMALE; GRAVES DISEASE; HUMANS; IODIDE PEROXIDASE; ISOENZYMES; PROPYLTHIOURACIL; THYROXINE; TRIIODOTHYRONINE;

EID: 0344034855     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1490443     Document Type: Article

References (14)

1. Meier CA & Burger AG. Effects of drugs and other substances on thyroid hormone. Synthesis and metabolism. In Werner and Ingbar's The Thyroid, 8th edition, pp 265-280. Eds LE Braverman & RD Utiger. Lippincott: Williams and Wilkins, Philadelphia, 2000.
2. Weetman AP, Tandon N & Morgan BP. Antithyroid drugs and the release of inflammatory mediators by complement-attacked thyroid cells. Lancet 1992 340 633-636.
3. Oppenheimer JH, Schwartz HL & Surks MI. Propylthiouracil inhibits the conversion Of L-thyroxine to L-triiodothyronine. An explanation of the anti-thyroxine effect of propylthiouracil and evidence supporting the concept that triiodothyronine is the active thyroid hormone. Journal of Clinical Investigation 1972 51 2493-2497.
4. Leonard JK & Rosenberg IN. Thyroxine 5′-deiodinase activity of rat kidney: observation on activation by thiols and inhibition by propylthiouracil. Endocrinology 1978 103 2137-2144.
5. Christensen LK, Skovsted L & Hansen JM. Protein-bound iodine during antithyroid treatment. Acta Medica Scandinavica 1969 185 483-487.
6. Hegedüs L, Hansen JM, Bech K, Kampmann JP, Jensen K, Andersen E et al. Thyroid stimulating immunoglobulins in Graves' disease with goitre growth, low thyroxine and increasing triiodothyronine during PTU treatment. Acta Endocrinologica 1984 107 482-488.
7. Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976 72 248-252.
8. Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HP et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. New England Journal of Medicine 2000 343 185-189.
9. 4 levels. Journal of Clinical Endocrinology and Metabolism 2003 88 594-598.
10. Abuid J & Larsen PR. Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents. Journal of Clinical Investigation 1974 54 201-208.
11. Ishii H, Inada M, Tanaka K, Mashio Y, Naito K, Nishikawa M et al. Triiodothyronine generation from thyroxine in human thyroid: enhanced conversion in Graves' thyroid tissue. Journal of Clinical Endocrinology and Metabolism 1981 52 1211-1217.
12. 4 5′-deiodinase activity in normal and abnormal human thyroid glands. Metabolism 1984 33 332-336.
13. Bianco AC, Salvatore D, Gereben, Berry MJ & Larsen PR. Biochemistry cellular and molecular biology and physiological roles of the iodothyronine selenodeiodinases. Endocrine Reviews 2002 23 38-89.
14. Salvatore D, Tu H, Harney JW & Larsen PR. Type 2 iodothyronine deiodinase is highly expressed in human thyroid. Journal of Clinical Investigation 1996 98 962-968.